Michael C. Badia

Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture−Activity Relationships

Paul S. Charifson, Anne‐Laure Grillot, Trudy H. Grossman et al. · Journal of Medicinal Chemistry · 2008 · 222 citations · Full text

Bioorganic Chemistry, Antibacterial Activity, Molecular Biology +23

(Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline, a novel orally active inhibitor of ACE

Donald S. Karanewsky, Michael C. Badia, David W. Cushman et al. · Journal of Medicinal Chemistry · 1988 · 106 citations · Full text

Pharmaceutical Science, Bioorganic Chemistry, Cardiovascular Pharmacology +16

Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase

Steven Ronkin, Michael C. Badia, S.F. Bellon et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 104 citations

Antifungal Agent, Medicine, Bacterial Gyrase +9

Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506

David M. Armistead, Michael C. Badia, David D. Deininger et al. · Acta Crystallographica Section D Biological Crystallography · 1995 · 54 citations

Phosphorus-containing inhibitors of HMG-CoA reductase. I. 4-[(2-Arylethyl)hydroxyphosphinyl]-3-hydroxybutanoic acids: a new class of cell selective inhibitors of cholesterol biosynthesis

Donald S. Karanewsky, Michael C. Badia, Carl P. Ciosek et al. · Journal of Medicinal Chemistry · 1990 · 51 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biosynthesis +14